Mitogen stimulation of peripheral blood lymphocytes of duodenal ulcer patients during treatment with cimetidine or ranitidine.
Open Access
- 1 May 1982
- Vol. 23 (5) , 398-403
- https://doi.org/10.1136/gut.23.5.398
Abstract
During a double-blind randomised clinical trial of cimetidine and ranitidine in the management of duodenal ulcer, the response of patients' peripheral blood lymphocytes to optimal mitogenic stimulation in vitro has been measured. Treatment with cimetidine, but not ranitidine, was associated with a significant increase in the proportion of peripheral blood lymphocytes responding to this optimal mitogenic stimulation. We conclude that these effects of cimetidine may not be mediated at classical histamine H2-receptors.This publication has 39 references indexed in Scilit:
- Ranitidine in the Treatment of Duodenal UlcerationScandinavian Journal of Gastroenterology, 1981
- Ranitidine--a new H2-receptor antagonist.Gut, 1980
- Development of asynchrony in growth of normal human lymphocytes during first day of culture after PHA stimulationExperimental Cell Research, 1980
- PHARMACOLOGICALLY EFFECTIVE PLASMA CONCENTRATIONS OF RANITIDINEThe Lancet, 1979
- ANTITUMOUR EFFECT OF CIMETIDINE?The Lancet, 1979
- Preliminary evidence for two subclasses of histamine H2-receptorsInflammation Research, 1979
- CIMETIDINE AND RENAL-ALLOGRAFT REJECTIONThe Lancet, 1978
- CIMETIDINE AND RENAL-ALLOGRAFT REJECTIONThe Lancet, 1978
- IDIOPATHIC CAROTIDITISThe Lancet, 1978
- Histamine suppression of human lymphocyte responses to mitogensCellular Immunology, 1978